Signal
While the FDA mulls whether to approve protagonist therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split profi
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-26 15:07 UTCUpdated 2026-02-26 15:17 UTC
rss
fierce_pharma
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Coverage centers on: While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split pr.
Score total
0.7
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
50%
All evidence
All evidence
While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split profits with Takeda.
Fierce Biotech · fiercebiotech.com · 2026-02-26 15:07 UTC
While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split profits with Takeda.
Fierce Pharma (All) · fiercepharma.com · 2026-02-26 15:17 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- fiercepharma.com (1)